Scilex Holding Announced That It Signed An Insurance Coverage Agreement For ELYXYB With A National PBM, For Their Medicare Population Potentially Expanding Coverage Of ELYXYB
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding has signed an insurance coverage agreement for ELYXYB with a national PBM for their Medicare population, which could expand the coverage of ELYXYB. ELYXYB is a treatment for acute migraine that has shown effectiveness in clinical studies, providing pain relief in as little as 15 minutes. Clinicians have indicated a need for alternatives to triptan therapy, and ELYXYB aligns with these needs.
December 12, 2023 | 2:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scilex Holding's agreement with a national PBM for ELYXYB coverage could lead to increased usage and revenues, as it meets clinician-identified needs for acute migraine treatment.
The insurance coverage agreement for ELYXYB is likely to increase its accessibility and usage among Medicare patients, which can lead to higher revenues for Scilex Holding. Given the clinical need for alternatives to triptan therapy and ELYXYB's positive clinical results, the agreement is significant for Scilex's financial outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100